C-Type Natriuretic Peptide (1-22), human CAS NO.127869-51-6

The mechanism of action involves binding to and activation of the natriuretic peptide receptor B (NPR-B), a transmembrane guanylyl cyclase-coupled receptor expressed in various tissues including vascular endothelium, bone, and the cardiovascular system. Receptor engagement stimulates intracellular guanylyl cyclase activity, leading to increased production of cyclic GMP (cGMP) and activation of downstream signaling pathways including cGMP-dependent protein kinases. This signaling cascade mediates vasodilation, inhibits vascular smooth muscle cell proliferation, promotes bone growth through endochondral ossification, and regulates fluid and electrolyte balance. The peptide's biological activity is dependent on its native conformation maintained by the intramolecular disulfide bond between Cys6 and Cys22, which is essential for proper receptor binding and activation.

This human CNP-22 peptide is indicated for research use only in preclinical studies investigating natriuretic peptide biology, cardiovascular regulation, bone growth mechanisms, and related physiological processes. It serves as a specific ligand for NPR-B receptor binding assays, functional cGMP accumulation assays, and in vitro studies of vascular relaxation, osteoblast differentiation, and chondrocyte proliferation. The product is also used in animal models to study the physiological effects of CNP on blood pressure regulation, bone development, and cardiovascular function. It is particularly valuable for research on conditions such as hypertension, heart failure, skeletal dysplasias, and vascular disorders where CNP signaling may be implicated. The product is not intended for diagnostic, therapeutic, or clinical applications in humans or animals.

As a research reagent, C-Type Natriuretic Peptide (1-22), human does not have established clinical efficacy for therapeutic use in human patients. This synthetic peptide has not undergone clinical development or received regulatory approval for any medical indication. While CNP and related natriuretic peptides have been investigated in preclinical studies and some early clinical trials for conditions such as skeletal dysplasias and cardiovascular diseases, this specific research-grade product remains an investigational tool used primarily for basic science and drug discovery research. It has no proven clinical efficacy or safety profile for human use and is intended solely for laboratory research applications in appropriate scientific settings.